Document Detail


Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution.
MedLine Citation:
PMID:  9415275     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: We have shown that basic fibroblast growth factor (bFGF/FGF-2) enhances myocardial collateral development in a canine model of progressive coronary occlusion when delivered via the left atrial or intracoronary routes; however, we have found intravenous bFGF ineffective in the same model. Data on the fate and efficacy of intravenous bFGF are limited. We hypothesized that first pass lung uptake might limit myocardial bFGF availability after intravenous injection. We postulated that delivery of bFGF through the distal port of a wedged Swan Ganz catheter might circumvent this problem by restricting exposure of bFGF to a limited number of pulmonary binding sites. This study evaluated differential regional uptake of 125I labeled bFGF following bolus intravenous, Swan Ganz, left atrial, intracoronary, and pericardial delivery. METHODS: Mongrel dogs were used. Human recombinant bFGF, monoiodinated with 125I, was mixed with cold bFGF to a specific activity of 0.03 microCi/microgram. Approximately 100 micrograms/kg was injected per animal by the intravenous, left atrial, Swan Ganz, intracoronary, or pericardial route. Dogs were killed 15 min or 150 min later. The heart, lungs, liver, spleen, and kidneys were harvested and 125I activity was assessed. Immunohistochemical and pharmacokinetic studies were also performed. RESULTS: Serum half life of bFGF was comparable after intracoronary, intravenous and left atrial delivery (50 min); however, there were significant differences with regard to pharmacodynamics. After intracoronary administration, 3-5% of the total bFGF dose was recovered from the heart, with the peptide immunolocalized to the extracellular matrix and vascular endothelium. In contrast, only 1.3% of the injected bFGF was localized to the heart after left atrial administration and 0.5% was recovered after intravenous or Swan Ganz delivery. Pericardial administration resulted in substantial cardiac bFGF delivery; 19% was present at 150 min. Myocardial uptake was similar with Swan Ganz and intravenous delivery, suggesting that the administered dose did not saturate available pulmonary binding sites. CONCLUSIONS: These data predict efficacy of intracoronary, left atrial, and pericardial bFGF for myocardial angiogenesis, and a lack of efficacy after bolus intravenous and Swan Ganz administration.
Authors:
D F Lazarous; M Shou; J A Stiber; D M Dadhania; V Thirumurti; E Hodge; E F Unger
Related Documents :
18665205 - Diagnostic tools for atrial tachyarrhythmias in implantable pacemakers: a review of tec...
7770365 - Relationship between interatrial conduction times and left atrial dimension in patients...
2620315 - The effect of atrial dilatation on the genesis of atrial arrhythmias.
6160555 - An experimental method for thermal control of heart rate: work in progress.
8712485 - A massive calcified left ventricular aneurysm with normal coronary arteries and without...
6662615 - The role of exercise testing soon after acute myocardial infarction.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Cardiovascular research     Volume:  36     ISSN:  0008-6363     ISO Abbreviation:  Cardiovasc. Res.     Publication Date:  1997 Oct 
Date Detail:
Created Date:  1998-02-13     Completed Date:  1998-02-13     Revised Date:  2003-11-14    
Medline Journal Info:
Nlm Unique ID:  0077427     Medline TA:  Cardiovasc Res     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  78-85     Citation Subset:  IM    
Affiliation:
Experimental Physiology and Pharmacology Section, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA. lazaroud@gwgate.nhlbi.nih.gov
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Catheterization, Swan-Ganz
Collateral Circulation / drug effects*
Coronary Circulation
Dogs
Endothelium, Vascular / metabolism
Extracellular Matrix / metabolism
Female
Fibroblast Growth Factor 2 / administration & dosage,  analysis,  pharmacokinetics*
Half-Life
Heart Atria
Immunohistochemistry
Injections, Intra-Arterial
Injections, Intravenous
Iodine Radioisotopes / diagnostic use
Kidney / chemistry,  metabolism
Liver / chemistry,  metabolism
Lung / chemistry,  metabolism
Male
Myocardium / chemistry,  metabolism*
Pericardium
Pulmonary Artery
Spleen / chemistry,  metabolism
Chemical
Reg. No./Substance:
0/Iodine Radioisotopes; 103107-01-3/Fibroblast Growth Factor 2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Membrane phosphorylation protects the cardiac sarcoplasmic reticulum Ca(2+)-ATPase against chlorinat...
Next Document:  Increased Ca2+ sensitivity of contractile elements via protein kinase C in alpha-toxin permeabilized...